S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
CGC   20.29 (+15.02%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
BAC   32.84 (+0.46%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
CGC   20.29 (+15.02%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
BAC   32.84 (+0.46%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
CGC   20.29 (+15.02%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
BAC   32.84 (+0.46%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
CGC   20.29 (+15.02%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
BAC   32.84 (+0.46%)
DIS   146.90 (-0.02%)
Log in

Prothena Stock Price, Forecast & Analysis (NASDAQ:PRTA)

$11.14
+0.39 (+3.63 %)
(As of 11/21/2019 04:00 PM ET)
Today's Range
$10.52
Now: $11.14
$11.40
50-Day Range
$7.46
MA: $8.73
$11.00
52-Week Range
$6.71
Now: $11.14
$14.77
Volume274,437 shs
Average Volume269,353 shs
Market Capitalization$444.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRTA
CUSIPN/A
Phone011-353-1236-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$950,000.00
Book Value$8.10 per share

Profitability

Net Income$-155,650,000.00
Net Margins-10,450.00%

Miscellaneous

Employees59
Market Cap$444.45 million
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.


Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) issued its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.05. The biotechnology company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.15 million. Prothena had a negative net margin of 10,450.00% and a negative return on equity of 26.02%. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

3 brokers have issued 1-year price targets for Prothena's shares. Their forecasts range from $9.00 to $14.00. On average, they expect Prothena's share price to reach $12.26 in the next year. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Prothena.

What is the consensus analysts' recommendation for Prothena?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena.

Has Prothena been receiving favorable news coverage?

Media coverage about PRTA stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prothena earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Prothena.

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BIOLINERX LTD/S (BLRX), Perrigo (PRGO), Celgene (CELG) and Synergy Pharmaceuticals (SGYP).

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rhumbline Advisers (0.16%), California Public Employees Retirement System (0.16%), Russell Investments Group Ltd. (0.14%), Campbell & CO Investment Adviser LLC (0.12%), Focused Wealth Management Inc (0.03%) and Meeder Asset Management Inc. (0.02%). View Institutional Ownership Trends for Prothena.

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Rhumbline Advisers. View Insider Buying and Selling for Prothena.

Which institutional investors are buying Prothena stock?

PRTA stock was acquired by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, California Public Employees Retirement System, Meeder Asset Management Inc. and Focused Wealth Management Inc. View Insider Buying and Selling for Prothena.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $11.14.

How big of a company is Prothena?

Prothena has a market capitalization of $444.45 million and generates $950,000.00 in revenue each year. The biotechnology company earns $-155,650,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Prothena employs 59 workers across the globe.View Additional Information About Prothena.

What is Prothena's official website?

The official website for Prothena is http://www.prothena.com/.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]


MarketBeat Community Rating for Prothena (NASDAQ PRTA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  482 (Vote Outperform)
Underperform Votes:  359 (Vote Underperform)
Total Votes:  841
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel